Clene Inc.
$ 4.29
9.44%
06 Feb - close price
- Market Cap 50,529,000 USD
- Current Price $ 4.29
- High / Low $ 4.35 / 4.01
- Stock P/E N/A
- Book Value -1.21
- EPS -3.44
- Next Earning Report 2026-03-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -17.38 %
- 52 Week High 13.50
- 52 Week Low 2.28
About
Clene Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, dedicated to pioneering clean-surface nanotechnology (CSN) therapies targeting neurodegenerative diseases and other significant health challenges. The company is currently navigating advanced clinical trials to substantiate the safety and efficacy of its innovative product pipeline, positioning itself as a potential leader in the biopharmaceutical sector. With a strong scientific foundation and a clear focus on transformative healthcare solutions, Clene offers a compelling investment opportunity for institutional investors seeking to support impactful medical advancements.
Analyst Target Price
$31.86
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-11 | 2025-08-14 | 2025-05-06 | 2025-03-11 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-03-13 | 2023-11-07 | 2023-08-14 | 2023-05-12 | 2023-03-13 |
| Reported EPS | -0.6084 | -0.78 | -0.4995 | -1.3646 | -1.1074 | -1.06 | -0.09 | -0.06 | -0.02 | -0.29 | -0.15 | -0.01 |
| Estimated EPS | -0.5633 | -0.07 | -0.784 | -0.878 | -1.32 | -1.49 | -0.08 | -0.07 | -0.09 | -0.12 | -0.14 | -0.12 |
| Surprise | -0.0451 | -0.71 | 0.2845 | -0.4866 | 0.2126 | 0.43 | -0.01 | 0.01 | 0.07 | -0.17 | -0.01 | 0.11 |
| Surprise Percentage | -8.0064% | -1014.2857% | 36.2883% | -55.4214% | 16.1061% | 28.8591% | -12.5% | 14.2857% | 77.7778% | -141.6667% | -7.1429% | 91.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-23 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.74 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLNN
2026-01-29 15:02:05
A major shareholder of Clene (NASDAQ:CLNN), Chidozie Ugwumba, sold 6,418 shares of the company's stock on January 26th at an average price of $5.02, totaling over $32,000. This is part of a series of transactions between January 13-28 where Ugwumba sold more than 128,000 shares for approximately $646,400. Despite these insider sales and negative earnings, analysts maintain a "Moderate Buy" rating for Clene with a consensus price target of $32.60.
2026-01-29 02:32:28
Clene (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 8,717 shares of the company's stock on January 28, 2026, for $4.91 per share, reducing his stake to 580,329 shares. This is part of a pattern of selling throughout January, resulting in a 1.48% decrease in his ownership. The stock traded down by 5.4% to $4.91 on the day of the sale, and analysts currently have a "Moderate Buy" rating with an average target price of $32.60.
2026-01-23 23:27:21
Chidozie Ugwumba, a major shareholder of Clene (NASDAQ:CLNN), sold 12,665 shares of the company's stock on January 22nd, valued at $67,377.80. This transaction was part of a series of insider sales from January 8-23, totaling 153,959 shares and generating approximately $806,600. After the January 22nd sale, Ugwumba still directly owned 605,159 shares, representing a 2.05% decrease in his stake.
2026-01-23 23:27:21
Chidozie Ugwumba, a major shareholder in Clene (NASDAQ:CLNN), sold 5,556 shares of the company's stock on January 23, 2026, for a total of $29,280.12. This sale is part of a larger series of transactions between January 8-23, totaling approximately 153,959 shares sold for about $807,000, reducing his stake to 599,603 shares. Clene's stock traded down 2% to $5.31, with analysts maintaining a "Moderate Buy" rating and an average price target of $32.60 despite negative EPS.
2026-01-23 01:02:00
Clene (NASDAQ:CLNN) has secured an in-person Type C meeting with the FDA to discuss biomarker and survival data for its ALS candidate, CNM-Au8, as it pursues accelerated approval. The company plans to file a New Drug Application in Q2 if the FDA agrees with its biomarker-survival linkage, with a potential regulatory decision by summer. Clene recently raised $6 million in financing, extending its operational runway, with further tranches tied to regulatory milestones.
2026-01-22 15:58:21
Ugwumba Chidozie, a ten percent owner of Clene Inc. (NASDAQ:CLNN), sold 32,474 shares of common stock in multiple transactions between January 16 and January 21, 2026, totaling approximately $161,519. Despite these sales, Chidozie, through Symbiosis II, LLC, still indirectly holds 617,824 shares. In related news, Clene Inc. raised over $28 million to advance its ALS drug candidate, CNM-Au8, and received positive biomarker data, with the FDA granting a Type C meeting to discuss the data for accelerated approval.
